Drug Information

Drug General Information
Drug ID
D01WZL
Former ID
DIB016992
Drug Name
AVE-8112
Synonyms
AVE8112
Indication Parkinson's disease [ICD9: 332; ICD10:G20] Phase 1 [524229]
Company
The michael j. fox foundation for parkinson's research; sanofi us
Target and Pathway
Target(s) Type IV phosphodiesterase Target Info Inhibitor [544367]
CAMP-specific 3',5'-cyclic phosphodiesterase 4B Target Info Inhibitor [544367]
CAMP-specific 3',5'-cyclic phosphodiesterase 4A Target Info Inhibitor [544367]
KEGG Pathway Purine metabolism
cAMP signaling pathway
Morphine addictionhsa00230:Purine metabolism
Morphine addiction
NetPath Pathway IL5 Signaling Pathway
IL2 Signaling Pathway
PathWhiz Pathway Purine Metabolism
Reactome DARPP-32 events
G alpha (s) signalling eventsR-HSA-180024:DARPP-32 events
G alpha (s) signalling events
WikiPathways G Protein Signaling Pathways
Myometrial Relaxation and Contraction Pathways
TSH signaling pathwayWP35:G Protein Signaling Pathways
Nuclear Receptors Meta-Pathway
Opioid SignallingWP35:G Protein Signaling Pathways
References
Ref 524229ClinicalTrials.gov (NCT01803945) A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease. U.S. National Institutes of Health.
Ref 544367Therapy for Parkinson's Disease: What is in the Pipeline?. Neurotherapeutics. 2014 January; 11(1): 24-33.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.